Xenexus Pharmaceuticals is building a pipeline of small molecule therapeutics based on drug repurposing. They offer the prospect of multi-target drugs with broad applicability across a range of complex diseases. The portfolio includes the following projects.
XEN-101 is for the treatment and prevention of Alzheimer's disease.
XEN-102 is a treatment to stimulate liver regeneration following partial hepatectomy and liver transplantation in order to prevent postoperative liver failure.
XEN-103 is a treatment for osteoarthritic pain with a better safety profile than currently available drugs.
XEN-104 is a treatment for postoperative pain.
The company's strategy is to progress its drug candidates into early clinical trials and then to out license to a large pharmaceutical partner for onward development and commercialisation.